{"id":"W1984547199","doi":"10.1007/s00280-006-0347-x","title":"A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Celecoxib; Cyclophosphamide; Clinical endpoint; Renal cell carcinoma; Internal medicine; Progressive disease; Toxicity; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Chemotherapy; Urology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001280856,0.001390642,0.003407545,0.0004716885,0.0007244391,0.001395962,0.001076789,0.001589755,0.005111867],"category_scores_gemma":[0.001373285,0.0006994774,0.001699204,0.000653491,0.001579883,0.001197095,0.0004755224,0.004890559,0.0009867108],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001224902,"about_ca_system_score_gemma":0.002385573,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002489197,"about_ca_topic_score_gemma":0.005243257,"domain_scores_codex":[0.9995574,0.0001829268,0.00002302615,0.00008859624,0.00002979507,0.0001182217],"domain_scores_gemma":[0.9986571,0.000251451,0.0001400462,0.0001141375,0.00006934297,0.000767984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9267591,0.02806465,0.002832419,0.0003835009,0.0007618249,0.000137525,0.0001388338,0.0007694977,0.007951927,0.000126655,0.001579761,0.0304943],"study_design_scores_gemma":[0.8598508,0.1339013,0.004145265,0.00001168646,0.0002382155,0.00007474759,0.00004643786,0.0003556651,0.0005161224,0.00006607753,0.0007809949,0.00001267329],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934366,0.002014518,0.0002627916,0.0007389246,0.0002575447,0.001238546,0.0005859853,0.00005905528,0.00140595],"genre_scores_gemma":[0.9911142,0.001839789,0.0008088187,0.0009522233,0.0003268012,0.001300879,0.001537664,0.00002110789,0.002098526],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005111867,"threshold_uncertainty_score":0.01710093,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005171539790784135,"score_gpt":0.2636782597352365,"score_spread":0.2585067199444524,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}